Literature DB >> 18474173

Prevention of diabetes and left ventricular hypertrophy with AT1 receptor blockade for hypertension.

Robert M Carey.   

Abstract

Entities:  

Year:  2008        PMID： 18474173     DOI： 10.1007/s11906-008-0018-x

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  10 in total

1.  Putting LIFE into hypertension.

Authors:  Michael A Weber
Journal:  Curr Hypertens Rep       Date:  2002-08       Impact factor: 5.369

2.  Left ventricular hypertrophy reversal and prevention of diabetes: two birds with one stone?

Authors:  Giuseppe Schillaci; Matteo Pirro; Elmo Mannarino
Journal:  Hypertension       Date:  2007-09-24       Impact factor: 10.190

3.  Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

Authors:  T W Gress; F J Nieto; E Shahar; M R Wofford; F L Brancati
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

4.  Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis.

Authors:  William J Elliott; Peter M Meyer
Journal:  Lancet       Date:  2007-01-20       Impact factor: 79.321

5.  The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension.

Authors:  A Moan; T Risanger; I Eide; S E Kjeldsen
Journal:  Blood Press       Date:  1994-05       Impact factor: 2.835

6.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

7.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

8.  Microvascular function relates to insulin sensitivity and blood pressure in normal subjects.

Authors:  E H Serné; C D Stehouwer; J C ter Maaten; P M ter Wee; J A Rauwerda; A J Donker; R O Gans
Journal:  Circulation       Date:  1999-02-23       Impact factor: 29.690

9.  Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.

Authors:  Peter M Okin; Richard B Devereux; Eva Gerdts; Steven M Snapinn; Katherine E Harris; Sverker Jern; Sverre E Kjeldsen; Stevo Julius; Jonathan M Edelman; Lars H Lindholm; Björn Dahlöf
Journal:  Circulation       Date:  2006-03-13       Impact factor: 29.690

Review 10.  Reducing diabetes incidence through the inhibition of the renin-angiotensin system: a strategy for reducing cardiovascular mortality and morbidity?

Authors:  Luisa Zanolla; Corrado Vassanelli
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2007-07       Impact factor: 2.160
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.